Viewing Study NCT06942767

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 12:36 AM
Ignite Modification Date: 2026-05-25 @ 11:05 AM
Study NCT ID: NCT06942767
Status: NOT_YET_RECRUITING
Last Update Posted: 2025-04-27
First Post: 2025-04-17
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Sponsor: Qilu Pharmaceutical Co., Ltd.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Gastroesophageal Junction Adenocarcinoma View
None Gastric Adenocarcinoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None CLDN18.2, gastric or gastroesophageal junction (GEJ) adenocarcinoma View